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ABSTRACT: Insulin, insulin-like growth factors 1 and 2 (IGF-1 and -2, respectively), and
their receptors (IR and IGF-1R) are the key elements of a complex hormonal system that
is essential for the development and functioning of humans. The C and D domains of IGFs
(absent in insulin) likely play important roles in the diﬀerential binding of IGF-1 and -2 to
IGF-1R and to the isoforms of IR (IR-A and IR-B) and speciﬁc activation of these
receptors. Here, we attempted to probe the impact of IGF-1 and IGF-2 D domains (DI and
DII, respectively) and the IGF-2 C domain (CII) on the receptor speciﬁcity of these
hormones. For this, we made two types of insulin hybrid analogues: (i) with the C-
terminus of the insulin A chain extended by the amino acids from the DI and DII domains
and (ii) with the C-terminus of the insulin B chain extended by some amino acids derived
from the CII domain. The receptor binding aﬃnities of these analogues and their receptor
autophosphorylation potentials were characterized. Our results indicate that the DI domain
has a more negative impact than the DII domain does on binding to IR, and that the DI
domain Pro-Leu-Lys residues are important factors for a diﬀerent IR-A versus IR-B binding
aﬃnity of IGF-1. We also showed that the additions of amino acids that partially “mimic” the CII domain, to the C-terminus of
the insulin B chain, change the binding and autophosphorylation speciﬁcity of insulin in favor of the “metabolic” IR-B isoform.
This opens new venues for rational enhancement of insulin IR-B speciﬁcity by modiﬁcations beyond the C-terminus of its B
chain.
I nsulin, insulin-like growth factors 1 and 2 (IGF-1 and -2,respectively), and their cognate cell surface receptors,
together with IGF-binding proteins (IGFBP-1−6), form a
complex hormonal/signaling system that is essential for the
development and functioning of humans. Its deregulation leads
to increased cancer risk, diabetes mellitus type 1 and 2, and
other disorders, such as obesity and metabolic syndrome.1,2
Insulin is a small (51 amino acids) protein hormone that is
the main regulator of glucose homeostasis. The mature insulin
is the post-translational product of a single-chain (pre)-
proinsulin, where the C peptide connecting A and B chains is
proteolytically, and speciﬁcally, cleaved oﬀ. This results in a
two-chain (A1−A21 and B1−B30) hormone, with two
interchain disulﬁde bridges (A7−B7 and A20−B19) and one
intrachain disulﬁde bridge (A6−A11) (Figure 1). The overall
tertiary structure, chain organization, and arrangement of the
disulﬁde bridges are conserved in members of the insulin-like
family such as IGFs, relaxins, bombyxins, insulin-like peptides,
etc.3
In contrast to insulin, IGF-1 and IGF-2 are single-chain
hormones (70 and 67 amino acids, respectively) involved
mainly in cell growth and protection against apoptosis.4,5 Both
IGFs share a high degree of sequence homology, which is also
extended to insulin (see Figure 1). They consist of four
domains, B, C, A, and D, with their B and A domains
corresponding to the B and A chains of insulin. C segments of
IGFs that span the B and A domains are structural analogues of
insulin C peptide, but without sequence similarity. The unique
D domains of IGFs [without equivalents in (pro)insulin]
extend the C-terminus of the A domains (Figure 1).
Insulin and IGFs elicit their biological eﬀects by binding to
the insulin receptor isoforms (IR-A and IR-B), and the insulin-
like growth factor receptor 1 (IGF-1R), while circulating IGF-
binding proteins modulate bioavailability of both IGFs.6
Moreover, IGF-2 binds speciﬁcally to the distinct insulin-like
growth factor receptor 2 (IGF-2R), which is a cation-
independent mannose 6-phosphate receptor that is likely
responsible for the clearance of IGF-2 from the cell surface
and for the preclusion of IGF-2:IGF-1R/IR interactions.4 The
IR and IGF-1R receptors are transmembrane glycoproteins
consisting of two α and two β subunits, which are connected by
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disulﬁde bridges to create (αβ)2 dimers. The extracellular α
parts of the IR contain hormone-binding regions, and the
membrane-anchored parts β contain intracellular tyrosine
kinase domains.7−9 The functional heterogeneity of IR arises
from an alternative splicing of exon 11 located at the C-
terminus of the α subunit, which results in two isoforms, IR-B
and IR-A, with diﬀerent C-terminal αCT peptides (IR-B and
IR-A, ±12 amino acids). The IR isoforms are expressed in a
tissue-speciﬁc manner in humans. IR-B is the main IR form for
insulin glycemic response-sensitive tissues (liver, muscles, and
adipose tissue), while IR-A is a dominant IR isoform in the
brain.10−12 Insulin and IGF-1 bind preferentially to their
cognate receptors (IR-A/IR-B and IGF-1R, respectively) at
subnanomolar concentrations. However, both hormones can
also cross-bind to their receptors (but with signiﬁcantly lower
aﬃnities), with the exception of IGF-2 that binds with relatively
high aﬃnity to both IR-A and IGF-1R.13−15
Simultaneous engagement of two, distinct hormone-binding
sites, so-called site 1 and site 2, on insulin and IGF receptors is
required for the high-aﬃnity binding complex.16 The recent
crystallographic studies showed that site 1 on both IR and IGF-
1R receptors is similar, involving some L1 domain surface and
the αCT peptide, which interact with the respective binding
sites 1 on insulin and IGFs (in A and B chains/domains)17,18 or
IGF-1.19 However, the nature of IR/IGF-1R-binding site 2 is
still understood only on the basis of mutagenesis studies.20−23
Although there is now relatively good insight into the roles of
A and B chains/domains of insulin and IGF-1 in the
hormone:IR/IGF-1R site 1 interactions, the functional impact
of the C and D domains of IGFs is much less understood. It is
envisaged, however, that they play some role in a diﬀerential
binding of IGF-1 and -2 to IR-A, IR-B, and IGF-1R, and
activation.24,25 The studies of the functional importance of the
IGF-1 C domain (CI domain), investigated in the context of
diﬀerent constructs of insulin,26,27 IGF-1,25,28 and IGF-2,24
revealed that it may play an important role in the IGF-1:IGF-
1R interaction, and in eliciting biological activity of this
hormone. However, it is detrimental to IGF-1:IR binding. It
was also proposed that the CI domain may interact with the CR
domain of the IGF-1R,29,30 but the recent crystal structure of
the complex of IGF-1 with IR L1-CR domains, mediated by the
IGF-1R αCT segment19 (Figure 2), did not yet clarify contacts
of the C and D domains with the receptor. In contrast to IGF-
1, the interaction of the shorter C domain of IGF-2 (CII) with
the CR domain is not anticipated.31,32 Although the role of the
CII domain has been much less studied, it has been shown that
the CI → CII swap in IGF-1 doubled the binding aﬃnities of
this IGF-1 analogue for IR-A and IR-B but diminished its
binding aﬃnity for IGF-1R to ∼25%.24
The role of DI and DII domains has been studied by several
groups,24,33,34 which showed that both DI and DII domains play
some roles in the activation of IR and IGF-1R, but they are
possibly less important in this process than the C domains.
Although the receptor-binding surfaces of insulin and both
IGFs have a similar side chain pattern,7,21,23,35 it is assumed that
each molecule uses a slightly diﬀerent IR-A, IR-B, or IGF-1R
binding mechanism,32 triggering subsequently speciﬁc signaling
cascades.14,36,37 Moreover, the diﬀerential binding of insulin
and IGFs to so-called hybrid receptors (receptor heterodimers
formed by IR-A/B and IR-A/IGF-1R αβ subunits) brings even
more complexity to the IGF/insulin system.38,39
Figure 1. Alignment of primary sequences of human IGF-1, IGF-2, and insulin. The gray background highlights evolutionarily conserved residues.
Arrows indicate the residues associated with the A−D domains of IGFs and the A and B chains of insulin.
Figure 2. Structures of insulin, IGF-1, and IGF-2 on the insulin
receptor L1-CR domains. All individual hormone structures have been
superimposed on the crystal structure of the IR L1-CR/IGF-1/IGF-1R
αCT-peptide complex (PDB entry 4xss), with the IR as the white
surface, IGF-1 in the 4xss complex colored dark gray, and the αCT
peptide colored bright yellow. The insulin molecule (gold/dark
yellow) was derived from the homologous IR L1-CR/insulin/1R αCT-
peptide structure (PDB entry 4oga). Free, noncomplexed IGF-1 [blue,
PDB entry 1gzr (to show C and D domains, not deﬁned in the 4xss
structure)], IGF-2 [pink, PDB entry 1igl (NMR model 1)], and insulin
were superimposed on the 8−18 Cα atoms of the B domain α helix in
the IGF-1 4xss complex. There is a 36−38 gap observed in the free
IGF-1 (1gzr) structure. A−D denote domains in these hormones
(color coding as in the individual molecules). Numbers assist terminal
residues seen in the individual structures. The conformations of the C
and D domains on the IR are putative, i.e., unchanged from their
noncomplexed structure, hence their clash with the IGF-1R αCT
peptide.
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Here, we aimed to elucidate further the roles of the DI, DII,
and CII domains in the speciﬁc functionality of these hormones:
their binding to IR-A, IR-B, and IGF-1R and their impact on
the autophosphorylation of these receptors. The human insulin
molecule was selected here as a template, as it has a high aﬃnity
for both IR isoforms; hence, it is much more sensitive probe
against these receptors. To address these issues, we made (i)
insulin analogues with the C-terminus of the A chain extended
by amino acids from the D domains of IGF-1 and IGF-2 and
(ii) insulin analogues with the C-terminus of the B chain
extended by amino acids mimicking the CII domain (Figure 3).
Despite a single-chain organization of IGF-1, the structure of
the IGF-1/IGF-1 α-CT/IR L1-CR complex19 showed that the
conformation of IGF-1 B domain residues 21−26 is almost
identical to the structure of equivalent insulin B22−B27
residues on the same receptor (Figure 2). This suggests that
at least the ﬁrst residues of the CI domain (invisible in this
complex) can follow the direction of the end part of the B
domain. As the IGF-2 and IGF-1 IR binding modes should be
similar, the insulin molecule can be considered as a useful
structural scaﬀold for the study of the role of CII residues in
binding of hormones to receptors. Receptor binding aﬃnities of
all analogues and their abilities to stimulate autophosphor-
ylation of the receptors were characterized, to correlate the
impact of the hormones’ modiﬁcations on their receptor
speciﬁcity.
■ EXPERIMENTAL PROCEDURES
Synthesis of Analogues 1−3. Synthesis of Insulin
Chains. The individual modiﬁed A chains and wild-type B
chain were prepared by total chemical solid-phase synthesis,
and SH groups of cysteines were converted to S-sulfonates as
previously described.40,41 Brieﬂy, Wang resins preloaded with
Fmoc amino acids (Novabiochem-Merck) were used to
synthesize the human insulin B chain and modiﬁed insulin A
chains (AA21-T-P-A-K-S-EA27-, AA21-P-L-K-P-A-K-S-AA29-, and
AA21-P-L-KA24- A chains) on an automatic solid-phase
synthesizer (ABI 433A, Applied Biosystems, Foster City,
CA). The used coupling reagents were HBTU/HOBt in
DMF. The Cys, His, Gln, and Asn side chains were protected
with Trt. The side chains of Tyr, Asp, Glu, Ser, and Thr were
protected with tBu, and the lysine side amino group was
protected with Boc. Peptides were cleaved from the resin with a
TFA/H2O/thioanisole/EDT/phenol/TIS mixture (92/2.2/
2.2/1/2.2/0.4) and precipitated from cold Et2O. Crude chains
(100 μmol) were dissolved and stirred in 25 mL of sulﬁtolysis
buﬀer [100 mM Tris, 250 mM Na2SO3, 80 mM Na2S4O6, and 7
M guanidine hydrochloride (pH 8.6)] for 3 h at room
temperature (RT). The chains were desalted on a Sephadex G-
10 column (4 cm × 85 cm) in 50 mM NH4HCO3 and puriﬁed
using reverse-phase high-performance liquid chromatography
(RP-HPLC) (Nucleosil C18 column, 250 mm × 21 mm, 5
μm).
Recombination of Insulin Chains. The method for the
formation of disulﬁde bonds in insulin analogues has been
described previously in detail.40,41 Brieﬂy, S-sulfonate deriva-
tives of the insulin A chain (30 mg) and B chain (15 mg) were
dissolved in 2 and 1 mL of degassed 0.1 M Gly/NaOH buﬀer
(pH 10.5), respectively. The exact molar concentration of each
chain was determined by UV spectroscopy at 280 nm using
molar extinction coeﬃcients of 3480 and 3230 M−1 cm−1 for
the A and B chains, respectively. Dithiothreitol (aliquots from
Pierce, catalog no. 20291) was added rapidly to the mixture of
both chains to give an SH/SSO3 molar ratio of 1.1/1. The
mixture was stirred in a capped vessel for 30−45 min at RT.
After the reduction, aerated 0.1 M Gly/NaOH (pH 10.5) buﬀer
was added to a ﬁnal 2/3 ratio of degassed and aerated buﬀers.
The resulting solution was stirred for an additional 48 h at 4 °C
in an open vessel to permit air oxidation.42 Glacial acetic acid (4
mL) was added to the mixture to terminate the reaction. The
resulting mixture was applied to a low-pressure column
(Sephadex G-50 in 1 M acetic acid, 2 cm × 75 cm). The
fractions containing analogues were puriﬁed using RP-HPLC
(Nucleosil C18 column, 250 mm × 8 mm, 5 μm). The
molecular weight of products was conﬁrmed by a HR mass
spectroscopy instrument (LTQ, Orbitrap XL, Thermo Fisher
Scientiﬁc, Waltham, MA). The purity of the analogues was
analyzed by RP-HPLC (Nucleosil C18 column, 250 mm × 4.6
mm, 5 μm) and was >95%.
Synthesis of Analogues 4−7. Synthesis of Peptide
Precursors. The G-F-F-Y-T-P-K(Pac)-T-S and G-F-F-Y-T-P-
K(Pac)T-S-K-V-S peptides were synthesized manually by a
stepwise coupling of the corresponding Fmoc-protected amino
acid on a 2-chlorotrityl resin using HBTU/DIPEA in 1-methyl-
2-pyrrolidinone (NMP). The completeness of the reaction was
controlled by a Kaiser test and quantiﬁed by measuring the
absorbance of the piperidine−dibenzofulvene complex after
Fmoc group deprotection. Synthesized peptides were cleaved
from the resin with a DCM/AcOH/triﬂuoroethanol mixture
(6/2/2) for 2 h at RT. The residues were evaporated to dryness
and treated with a DCM/TFA/TIS/H2O mixture (44/50/3/3)
for 2 h at RT. The mixture was evaporated in vacuo and treated
with diethyl ether. The solid residue after the diethyl ether
Figure 3. Schematic representation of structures of insulin analogues 1−7 prepared in this study. Insulin A and B chains and disulﬁde bridges are
shown as blue lines. The additional residues derived from the DI, DII, or CII domains are drawn in single-letter codes, with insulin numbering.
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extraction was dissolved in 40% acetonitrile in water with 0.1%
TFA and puriﬁed using RP-HPLC.
G-F-F-Y-T-P-K(Pac)T-S-K(Pac)V and G-F-F-Y-T-P-K(Pac)-
T-S-K(Pac) peptides were synthesized using an automatic
solid-phase synthesizer (ABI 433A, Applied Biosystems) by a
similar method described above but using 2-chlorotrityl resin.
Enzymatic Semisynthesis. Analogues 4−7 were prepared by
the enzymatic semisynthesis starting from des(B23−B30)-
octapeptide-insulin (DOI) and respective peptides. Analogue
4 was prepared according to the previously described
protocol.43,44 Semisyntheses of analogues 5−7 were performed
according to the slightly diﬀerent protocol published by
Nakagawa and Tager45 because of the lower solubility of
their precursor peptides. Brieﬂy, a peptide (30 mM) and DOI
(7.7 mM) were dissolved in an N,N-dimethylacetamide
(DMA)/1,4-butanediol/0.2 M Tris-HCl mixture (pH 8.0)
(7/7/6), supplemented with 10 mM Ca(Ac)2 and 1 mM EDTA
in a total volume of 400 μL. The reaction was initiated by the
addition of 2 mg of TPCK-treated trypsin. The pH of the
solution was adjusted to 6.9−7.0 by N-methylmorpholine. The
reaction mixture was incubated at 37 °C and monitored by RP-
HPLC (Nucleosil 120-5 C-18 column, 250 mm × 4.6 mm).
After 24−48 h, the reaction was stopped by the addition of
acetone and the product was isolated by RP-HPLC (Nucleosil
C18 column, 250 mm × 8 mm). The molecular weight was
conﬁrmed by HR mass spectroscopy (LTQ, Orbitrap XL,
Thermo Fisher Scientiﬁc).
Enzymatic Deprotection of Precursors of Insulin Ana-
logues. The enzymatic deprotection of Pac-protected ana-
logues was performed according to the previously described
protocol.43,46 The respective precursor of an insulin analogue
(4, 5, 6, or 7, ∼1 mg of each) with a phenylacetyl protecting
group (Pac) on Nε groups of lysine(s) was dissolved in 1 mL of
50 mM potassium phosphate buﬀer (pH 7.5). Protease
inhibitor cocktail (5 μL, Sigma-Aldrich, catalog no. P8465)
was added. The reaction was initiated by the addition of soluble
penicillin amidohydrolase (PA) and monitored via RP-HPLC
(Nucleosil C18 column, 250 mm × 4 mm). The reaction
proceeded at 37 °C. After 16 h, an extra amount of PA was
added. After completion of the deprotection (∼28 h), an
analogue was puriﬁed by RP-HPLC as described above. The
molecular weight was conﬁrmed by HR mass spectroscopy
(LTQ, Orbitrap XL, Thermo Fisher Scientiﬁc). The purity
(>96%) of analogues 4−7 was veriﬁed by RP-HPLC.
Cell Cultures. IM-9 cells (ATCC) were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 units/mL penicillin, and 100 μg/mL strepto-
mycin in humidiﬁed air with 5% CO2 at 37 °C.
Mouse embryonic ﬁbroblasts used for binding and signaling
were derived from animals with targeted disruption of the IGF-
1 receptor gene47 and stably transfected with expression vectors
containing either A (R−/IR-A) or B (R−/IR-B) isoforms of
human insulin receptor or human IGF-1 receptor (R+39).14,48
The cell lines were kindly provided by A. Belﬁore (University of
Magna Graecia, Catanzaro, Italy) and R. Baserga (Thomas
Jeﬀerson University, Philadelphia, PA). Cells were grown in
DMEM medium with 5 mM glucose (Biosera) supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 0.3 μg/mL
puromycin, 100 units/mL penicillin, and 100 μg/mL
streptomycin in humidiﬁed air with 5% CO2 at 37 °C.
Receptor Binding Studies. Human IM-9 Lymphocytes
(human IR-A isoform). Receptor binding studies with the
insulin receptor in membranes of human IM-9 lymphocytes
(containing only the human IR-A isoform) were performed and
Kd values determined according to the procedure described
recently in detail by Morcavallo et al.13 Binding data were
analyzed using the Excel algorithms speciﬁcally developed for
the IM-9 cell system in the laboratory of P. De Meyts (A. V.
Groth and R. M. Shymko, Hagedorn Research Institute,
Gentofte, Denmark, a kind gift of P. De Meyts) using a
method of nonlinear regression and a one-site ﬁtting program
and taking into account potential depletion of free ligand. Each
binding curve was determined in duplicate, and the ﬁnal
dissociation constant (Kd) of an analogue was calculated from
at least three (n ≥ 3) binding curves (Kd values) determined
independently. The dissociation constant of human 125I-labeled
insulin (PerkinElmer) was set to 0.3 nM.
Mouse Embryonic Fibroblasts (human IR-B isoform).
Receptor binding studies with the insulin receptor in
membranes of mouse embryonic ﬁbroblasts derived from
IGF-1 receptor knockout mice that solely expressed the human
IR-B isoform were performed as described in detail
previously.40,49 Binding data were analyzed, and the dissocia-
tion constant (Kd) was determined with GraphPad Prism 5
using a method of nonlinear regression and a one-site ﬁtting
program and taking into account potential depletion of free
ligand. Each binding curve was determined in duplicate, and the
ﬁnal dissociation constant (Kd) of each analogue was calculated
from at least three (n ≥ 3) binding curves (Kd values)
determined independently. The dissociation constant of human
125I-labeled insulin (PerkinElmer) was set to 0.3 nM.
Mouse Embryonic Fibroblasts (human IGF-1R). Receptor
binding studies with the IGF-1 receptor in membranes of
mouse embryonic ﬁbroblasts derived from IGF-1R knockout
mice and transfected with human IGF-1R were performed as
described previously.40 Binding data were analyzed and the
dissociation constants determined by the same method that was
used for IR-B. The dissociation constant of human [125I]IGF-1
(PerkinElmer) was set to 0.2 nM. Here we should note that the
use of bovine serum albumin in the binding buﬀer (e.g., Sigma-
Aldrich A6003) void of “IGF-binding-like” proteins, which
interfere with the binding assay, is essential.50
The signiﬁcance of the changes in binding aﬃnities of the
analogues, related to the insulin binding for all types of
receptors, was calculated using a two-tailed t test.
Stimulation of Cells. Cells (cell lines R+39, R−/IR-A, and
R−/IR-B) were seeded in 24-well plates (4 × 104 cells per well)
in 300 μL of DMEM and incubated for 24 h. Cells were
afterward starved for 4 h in serum-free medium. A ligand
(insulin, IGF-1, IGF-2, or an analogue) at ﬁnal concentrations
of 10−8 M was added to the medium in each well for 10 min.
The reaction was terminated by removal of the medium, and
the mixture was washed with ice-cold 0.9% NaCl and snap
frozen until the next manipulation. The series of ligands were
tested four times using diﬀerent batches of cells.
Immunoblotting. Cells were lysed in 50 μL of lysis buﬀer
containing 62.5 mM Tris-HCl (pH 6.8), 2% SDS (w/v), 10%
glycerol (v/v), 0.01% Bromphenol Blue (w/v), 0.1 M DTT (w/
v), 50 mM NaF, 1 mM Na3VO4, and 0.5% protease inhibitor
coctail (Sigma-Aldrich) by sonication. Proteins were routinely
analyzed using immunoblotting and horseradish peroxidase-
labeled secondary antibodies (Sigma-Aldrich). Cell extracts (10
μL containing 10 ± 0.8 μg of proteins) were separated on 10%
SDS−polyacrylamide gels and electroblotted to a PVDF
membrane. The membranes were probed with the following
antibodies: anti-phospho-IGF-1R β subunit (Tyr1131)/IRβ
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(Tyr1146), (Cell Signaling Technology), anti-human IR β
subunit (Invitrogen), and anti-IGF-1R β subunit (C-20) (Santa
Cruz Biotechnology, Santa Cruz, CA). The blots were
developed using the SuperSignal West Femto maximum
sensitivity substrate (Pierce) and analyzed using the ChemiDoc
MP Imaging System (Bio-Rad). The signal density generated
by each ligand in a particular experiment was expressed as the
contribution of phosphorylation relative to the respective
human insulin (R−/IR-A and R−/IR-B) IGF-1 (R+39) signal in
the same experiment. Mean ± standard error of the mean
(SEM) values were calculated from four independent experi-
ments. The signiﬁcance of the changes in stimulation of
autophosphorylation related to the stimulation by insulin was
calculated using one-way analysis of variance.
■ RESULTS
Design of the Analogues. The ﬁrst three insulin
analogues [1−3 (Figure 3)] have the C-terminus of the A
chain extended by amino acids from the N-terminal parts of the
IGF’s D domains. In analogue 1, the DI domain is represented
only by its ﬁrst three P-L-K amino acids, which are an “insert”
(or addition) to the DII domain (Figure 1); hence, they can be
considered as the DI domain “unique” feature. Here, we were
interested in their “isolated” (i.e., purely DI-like “signature”)
eﬀect on binding of these hormones. Analogues 2 and 3 contain
the entire D domains of IGF-1 and IGF-2, respectively.
Additionally, insulin’s A chain C-terminal AsnA21 has been
substituted in analogues 1−3 with alanine that is present in
both IGFs at that site; hence, the A21 site could be considered
here as part of the D domains.
The studies of the eﬀect of the CII domain on insulin
functionality were originally planned on hormone analogues
containing the full (or large fragments of) CII domain, which
would be enzymatically introduced into des(B23−B30)-
octapeptide-insulin (DOI), as the extensions of insulin C-
terminal octapeptide B22−B30.43 An alternative recombination
of the already extended B chain with the A chain was also tried
as described previously.40,41 However, all these attempts were
unsuccessful (see below); hence, for synthetic reasons, only the
ﬁrst four amino acids of the CII domain (with arginines also
replaced with lysines) were added after B30. This work resulted
in analogues 4−7 (Figure 3).
Synthesis of the Analogues. Analogues 1−3 were
prepared by the total chemical synthesis and chain recombi-
nation (folding) of insulin A and B chain S-sulfonates.40,41
Addition of amino acids from the D domains of IGFs to the C-
terminus of insulin A chain resulted in reduced yields of chain
recombination (2−5%), in comparison with the average
recombination eﬃciencies of native insulin (∼8−12%).40
Analogue 3 (with the DII domain) was obtained with a yield
(5.4%) better than those of analogues 1 and 2 containing DI
domain motifs (∼2%). Furthermore, all trials for synthesizing
the AA21PLA23-insulin analogue, which was designed to probe
the eﬀect of P-L substitution alone (like P-L-K), have never
yielded a suﬃcient amount of the material for its biological
characterization.
In the ﬁrst attempt toward the total chemical synthesis of an
insulin analogue with the whole CII domain, the insulin B chain
extended by the CII S-R-V-S-R-R-S-R amino acids of IGF-2 was
successfully made. However, its recombination with the insulin
A chain S-sulfonate form40,41 failed because of the insolubility
of this B chain derivative in the recombination buﬀer.
Therefore, a fully protected (t-Bu, Boc) G-F-F-Y-T-P-K-T-S-
K-V-S-K-K-S-K peptide containing C-terminal insulin octapep-
tide and amino acids of the CII domain was prepared. Here,
arginine residues in the original CII were substituted with
lysines to allow both easier side chain protection and enzymatic
coupling with DOI. The Nε-Boc-Lys protection was necessary
to shield this sequence against trypsin proteolysis during
analogue semisynthesis. Although a similar approach was
already used in the preparation of insulin with the CI domain,
27
the semisynthetic attachment of this peptide to DOI failed
Table 1. Receptor Binding Aﬃnities of Human Insulin, IGF-1, IGF-2, and the Insulin Analogues Reported in This Work
analogue
Kd ± SE (nM) (n) for
human IR-A in IM-9
lymphocytes
relative
binding
aﬃnitya for
human IR-A
(%)
Kd ± SE (nM) (n) for
human IR-B in mouse
ﬁbroblasts
relative
binding
aﬃnity for
human IR-B
(%)
Kd ± SE (nM) (n) for
human IGF-1R in
mouse ﬁbroblasts
relative binding aﬃnity for
human IGF-1R (%)
human insulinb 0.55 ± 0.04 (7)1 100 0.67 ± 0.17 (4) 100 ± 25 292 ± 31 (3)c 100 ± 11 0.08 ± 0.01
0.36 ± 0.06 (5)2
0.43 ± 0.00 (5)3
0.25 ± 0.02 (5)4
AA21PLKA24-insulin
(1)
1.19 ± 0.08*** (3)2 30.3 ± 2.0 2.51 ± 0.63** (4) 26.7 ± 6.7 877 ± 378* (3) 33.3 ± 14.4 0.03 ± 0.01
AA21PLKPAKSAA29-
insulin (2)
1.44 ± 0.06*** (3)2 25.0 ± 1.0 2.51 ± 0.36*** (4) 26.7 ± 3.8 274 ± 29 (3) 107 ± 11 0.09 ± 0.01
AA21TPAKSEA27-
insulin (3)
0.51 ± 0.04* (3)3 84.3 ± 6.6 1.26 ± 0.23*** (4) 53.2 ± 9.7 124 ± 22* (3) 235 ± 42 0.19 ± 0.03
SB31-insulin (4) 0.48 ± 0.01*** (3)4 52.1 ± 1.1 0.56 ± 0.11 (3) 120 ± 24 280 ± 41 (3) 104 ± 15 0.09 ± 0.01
SB31KB32-insulin (5) 1.28 ± 0.18*** (3)1 43.0 ± 6.0 2.03 ± 0.36*** (3) 33.0 ± 5.9 257 ± 16 (2)d 114 ± 7 0.09 ± 0.01
SB31KVB33-insulin (6) 0.41 ± 0.02 (3)2 87.8 ± 4.3 0.61 ± 0.07 (3) 110 ± 13 195 ± 33 (3) 150 ± 25 0.12 ± 0.02
SB31KVSB34-insulin
(7)
0.57 ± 0.19 (3)3 75.4 ± 25.1 0.45 ± 0.13* (4) 149 ± 43 234 ± 99 (2)d 125 ± 53 0.10 ± 0.03
human IGF-1 23.8 ± 6.6*** (3)4 1.1 ± 0.3 224 ± 16*** (4) 0.30 ± 0.02 0.24 ± 0.05*** (5)c 1217 ± 254 100 ± 21
human IGF-2 2.92 ± 0.14*** (3)4 8.6 ± 0.4 35.5 ± 5.6*** (4) 1.9 ± 0.3 2.32 ± 0.72*** (3) 126 ± 39 10.3 ± 3.2
aThe relative receptor binding aﬃnity (potency) is deﬁned as (Kd of human insulin or IGF/Kd of analogue) × 100.
bThe Kd of human insulin for IR-
A was determined in four independent measurements (1−4). The individual values of Kd of insulin analogues are relative to one of these Kd values of
human insulin (e.g., 1 to 1, etc.). cFrom ref 61. dThe Kd value represents the mean of two independent measurements ± range. Asterisks indicate that
binding of the ligand to a particular receptor diﬀers signiﬁcantly from that of insulin (*p < 0.05; **p < 0.01; ***p < 0.001).
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again because of its insolubility. Hence, we employed a more
limited and pragmatic approach, in which the C-terminus of
insulin B chain octapeptide was systematically expanded by the
subsequent residues from the CII domain. This strategy resulted
in four CII derivatives of insulin B23−30 octapeptide, with
addition of S, S-K, S-K-V, or S-K-V-S amino acids, and all lysine
free Nε-groups were phenylacetyl-protected. In contrast to the
whole CII domain-modiﬁed B23−30 octapeptide, these
peptides were successfully attached enzymatically to the DOI.
However, the yields of the individual semisyntheses of
analogues 4−7 were only within the range of ∼1.5−5%.
Analogue 7 was obtained with the lowest yield, and the
eﬃciencies of semisyntheses for 4−7 were directly proportional
to the length of the respective peptide. Furthermore, the ﬁnal
removal of the phenylacetyl protection required use of the
cocktail protease inhibitors to protect these analogues against
proteolytic contaminants present in the penicillin amidohy-
drolase solution.
Receptor Binding Studies. The binding aﬃnities of all
analogues, human insulin, and human IGF-1 and IGF-2 for
human IR-A, IR-B, and IGF-1R are listed in Table 1.
IR-A Binding Aﬃnities. All insulin analogues 1−7 have
either similar, or lower, aﬃnity for IR-A in comparison with
that of human insulin. Hybrid molecules 1−3 containing motifs
from the D domains of IGF-1 and IGF-2 have diﬀerent impacts
on IR-A binding. Whereas analogue 3 (whole DII domain) has a
binding aﬃnity comparable to that of HI (84%), the binding
potencies of both analogues 1 (with the APLK fragment of the
DI domain) and 2 (with the whole DI domain) decreased to
less (or approximately) than one-third of HI binding potency.
The addition of amino acids mimicking the CII domain to
human insulin (analogues 4−7) has lowered their level of IR-A
binding to 43−88%. Interestingly, analogues with only one
(SB31, 4) or two (SB31KB32, 5) additional amino acids are less
active than analogues with three (6) or four (7) extra residues
from the CII domain (Table 1, Figure 4A, and Figure S1).
IR-B Binding Aﬃnities. The additions of the D domain
amino acids of IGF-1 and -2 to HI have a similar negative eﬀect
on the binding of analogues to both IR isoforms, but the
negative impact of the addition of the whole DII domain
(analogue 3) is more signiﬁcant on IR-B (53%) than on IR-A
(85%) aﬃnity.
The eﬀects of additions of CII domain amino acids to HI on
its binding to IR-B were rather surprising. Except analogue 5,
with only 33% HI binding aﬃnity, the other CII domain-derived
analogues have aﬃnities of IR-B similar to (4 and 6), or slightly
higher than (7), that of HI. Interestingly, the most potent
analogue, 7, contains the longest, four extra amino acids,
modiﬁcation from the CII domain (Table 1, Figure 4B, and
Figure S2).
IGF-1R Binding Aﬃnities. All analogues exhibited very low
binding aﬃnity for IGF-1R compared to the aﬃnity of IGF-1
for this receptor. In general, the analogues have binding
potencies similar to that of human insulin. The exceptions are
analogue 1, the IGF-1R binding aﬃnity of which is 3 times
lower, and analogue 3, which binds IGF-1R 2 times stronger
than HI (Table 1, Figure 4C, and Figure S3).
Autophosphorylation of IR and IGF-1R. Activation of
IR-A, IR-B, and IGF-1R was measured in R−/IR-A, R−/IR-B,
and R+39 cells, respectively, and by the detection of the
Figure 4. Comparison of relative binding aﬃnities (white bars) for IR-A (A), IR-B (B), and IGF-1R (C) and relative abilities to activate these
receptors (gray bars) of human insulin (HI), IGF-1, IGF-2, and insulin analogues containing sequences derived from the D domain of IGF-1 (1 and
2) or IGF-2 (3) or from the C domain of IGF-2 (4−7). The experimental values are related to binding potency and biological activity of HI (for IR-
A and IR-B) or IGF-1 (for IGF-1R). Asterisks indicate that binding of the ligand or autophosphorylation of a particular receptor induced by the
ligand diﬀers signiﬁcantly from that of insulin (*p < 0.05; **p < 0.01; ***p < 0.001). See also Table 1 and Experimental Procedures.
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autophosphorylation of IR Tyr1158 (IR-B numbering) or the
analogous IGF-1R Tyr1131. Cells were stimulated either by the
natural ligand (human IGF-1, IGF-2, or insulin) or by an
insulin analogue for 10 min, at a ligand concentration of 10 nM
each. The results are shown in Figure 4 in correlation with
binding aﬃnities of analogues. Representative immunoblots are
shown in Figure S4.
Generally, IR-A autophosphorylation abilities of the ana-
logues (Figure 4A) followed their IR-A binding trends. All
analogues exhibited a slightly reduced capability to activate IR-
A compared to that of human insulin; they were within IGF-2
activation range and were enhanced in relation to IGF-1.
The IR-B stimulation abilities of analogues 1−3 (with the DI
and DII domains) (Figure 4B) were comparable with that of
human insulin. However, “CII domain analogues” 4−6 showed
signiﬁcantly higher (2−3 times higher than that of HI) levels of
autophosphorylation of the IR-B. Interestingly, analogue 7, with
enhanced (150%) binding potency for IR-B, stimulated IR-B
like HI. Therefore, the IR-B receptor autophosphorylation
abilities of insulin analogues modiﬁed by fragments of the CII
domain are not really correlated with their binding potencies
for this receptor: analogues 4 and 6, strong activators of IR-B,
are equipotent with HI in IR-B binding, while analogue 5 (also
a good stimulant of IR-B) has only 33% of the IR-B binding
potency of HI.
The addition of sequences derived from DI, DII, and CII
domains to human insulin did not signiﬁcantly inﬂuence the
ability of these ligands to stimulate the autophosphorylation of
IGF-1R. All analogues 1−7 stimulated this receptor with an
eﬃciency comparable to that of human insulin (Figure 4C).
■ DISCUSSION
The C and D domains of IGF-1 and IGF-2 represent the major
structural diﬀerences between these growth factors and insulin
(Figure 1). However, it was proposed that the A and B domains
of IGFs are the main determinants of their speciﬁc binding and
activation of IGF-1R.16,20 This has been recently supported by a
similar mode of binding of insulin and IGF-1 to IR/IGF-1R
constructs observed in the respective crystal structures.17−19
Therefore, we can envisage that the roles of the C and D
domains are limited to more subtle modulation of binding of
IGF-1 and IGF-2 to IR-A, IR-B, and IGF-1R, and subsequent
tuning of their activation.24,51
Initial studies of insulin:D domain hybrids were reported in
the 1980s.33,34,52 Although they provided valuable data, insight
into binding aﬃnities of these analogues for individual
“isolated” IR isoforms and IGF-1R was not gained at that
time. Moreover, the understanding of the role of the IGF-2 CII
domain in the receptor selectivity of this hormone is still
limited.
These structural and functional ambiguities prompted us to
investigate whether insulin analogues, which carry DI, DII, and
CII domains, could be molecular probes for testing the
functionalities of these structural segments.
The sensitivity of interactions of insulin with IR-A and IR-B
and the feasibility of the chemical synthesis of insulin-based
analogues (in comparison to IGF-based scaﬀolds) were the
decisive factors in selection of this hormone as a working
template in this study.
The addition of amino acids from the DI domain (analogues
1 and 2) had a visible negative eﬀect on insulin IR-A and IR-B
binding aﬃnities [25−30% of that of HI (Table 1)]. This
conﬁrmed the previously proposed unfavorable interference of
the DI domain with binding to IR
34 and agrees with the
observation that deletion of the DI domain in IGF-1 doubles its
IR binding aﬃnity.25,26 Moreover, the DII → DI swap in IGF-2
also decreased its IR-A aﬃnity to 37%.24 Here, we have shown
that addition of the ﬁrst three amino acids of the DI domain (P-
L-K, analogue 1) to insulin A21 site is suﬃcient to lower its
level of IR-A binding. Unfortunately, we have not succeeded in
synthesizing the AA21-P-LA23 analogue with the short, initial DI
sequence. This analogue would help in understanding better
the functional signiﬁcance of these particular two amino acids
of the DI domain, as they represent a unique IGF-1 D domain
insert (in comparison with the shorter DII domain) (Figure 1).
Nevertheless, it seems that not the length of the DI domain but
its particular P-L-K sequence is the determining factor for the
diﬀerent IR-A and IR-B binding abilities of IGF-1 and IGF-2.
This underlines further the presence and role of the usually
structurally signiﬁcant proline residue at position 62 in the DI
domain, which may have a speciﬁc eﬀect on the conformation
of the D domain. It would amplify the interference of the DI
domain with the hormone’s binding site at IR, as its receptor-
bound conformation is likely diﬀerent from the DII-speciﬁc fold.
In contrast to that of the DI domain, the addition of the DII
domain to the insulin molecule (analogue 3) has a marginal
eﬀect (85%) on its IR-A binding and a relatively small negative
eﬀect (53%) on its aﬃnity for IR-B (Table 1). Although the
peculiar role of NA21 → AA21 substitution in analogues 1−3
cannot be ignored (this single mutation reduces the level of
insulin IR-A binding to ∼65%53,54), we assume that the IR
binding trends of these analogues are meaningful, as all of them
contain the AlaA21 mutation. Therefore, the diﬀerent binding
aﬃnities of analogue 3 for IR isoforms, compared to that of HI,
can result from the presence of the whole additional DII
domain, rather than from the impact of the AlaA21 mutation.
The relatively more important decrease in the IR-B binding
aﬃnity of analogue 3 compared to its eﬀect on IR-A could also
indicate that (i) the DII domain is, at least partly, responsible
for a lower aﬃnity of IGF-2 for IR-B and (ii) the DII domain
does not play a major role in the interaction with IR-A. Because
only the 12 additional amino acids at the C-terminus of the α
subunit (encoded by exon 11) are the diﬀerence between IR-A
and IR-B, some speciﬁc, unfavorable interaction of the DII
domain with the αCT segment of IR-B could be behind the
mechanism of the “DII-mediated” lower aﬃnity for IR-B. This
could also mean that the DII domain does not interact, or does
so in an only marginal fashion, with IR-A.
It may be expected that the addition of DI and DII domains
to insulin will, somehow, increase the IGF-1R aﬃnity of these
analogues. However, this eﬀect was only partially noted in the
DII domain-containing analogue 3. Its binding aﬃnity for IGF-
1R is >2 times higher than that of HI (Table 1 and Figure 4).
The nondeleterious eﬀect of the DII domain for IGF-1R was
observed also by Denley et al.,24 who found that the IGF-1
analogue with the added DII domain had a similar binding
aﬃnity for native IGF-1. It was rather surprising that the
binding aﬃnity for IGF-1R was not increased in the analogues
containing the whole DI domain (or its fragment, analogue 2 or
1, respectively), and that their binding aﬃnities were similar to
or signiﬁcantly lower than the aﬃnity of HI [analogue 2, 107%;
analogue 1, 33% (Table 1)]. Denley at al24 observed that
addition of the DI domain to IGF-2 enhanced 3-fold the IGF-
1R binding aﬃnity of the hybrid in comparison with that of
native IGF-2. Hence, it is possible that the role of the DI
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domain in binding to IGF-1R can diﬀer in the context of insulin
and IGF molecules.
All three (1−3) DI and DII analogues show a similar ability to
activate IR-A (Figure 4A and Figure S4), despite their relatively
diﬀerent IR-A binding aﬃnities [25−84% (Table 1)]; these IR-
A stimulation properties are also lower than those of HI and
IGF-2. Moreover, the autophosphorylation of IR-A by
analogues 1−3 does not simply, and fully, correlate with their
binding aﬃnities, and the insertion of DI and DII domains into
insulin has a less negative impact on IR-A autophosphorylation
than on binding. The activations of IR-B by analogues 1−3 are
also similar; however, in comparison with the autophosphor-
ylation of IR-A, their eﬀect is less pronounced here, and these
analogues are also able to activate IR-B better than IGF-2
(Figure 4B and Figure S4). This suggests that the core of the
hormone(s) (insulin or IGF) plays a more important role in
these processes than the D domains. Similar eﬀects can be seen
in the autophosphorylation of IGF-1R, where analogues 1−3
stimulate the receptor at the HI level, and much more weakly
than both IGFs (Figure 4C and Figure S4).
The second part of our work here concerned whether the
incorporation of the elements of the CII domain into insulins
template (analogues 4−7) would allow us to monitor their
impact on hormone:receptor speciﬁcity. It must be stressed that
the reports concerning the signiﬁcance of the CI and CII
domains (or particular amino acids) are infrequent, and studies
of the CII domain are especially limited.
24−28,55,56 This results
likely from the methodological barrier, i.e., diﬃcult synthesis of
this particular amino acid sequence. For example, the high
content of arginine in the CII domain decreases signiﬁcantly the
solubility of these peptides. Hence, this was also the main
reason behind our unsuccessful synthesis of the insulin
analogue with the entire CII domain. Furthermore, the Arg
residues interfere also with the trypsin-catalyzed semisynthesis
of the analogue, as the Arg-involving peptide bonds are digested
even under the tryptic-digest unfavorable conditions (e.g., pH 7
and organic solvent). Therefore, we had to include Arg → Lys
substitutions in the CII domain, which is similar to the approach
of the previous study concerning the CI domain of IGF-1.
27
Here, we also tried to use the Boc protection of Lys to prepare
an analogue containing the entire CII-like domain (G
B23FFY-
TPKTSKVSKKSKB38) by trypsin-catalyzed semisynthesis.
Unfortunately, the 16-amino acid peptide precursor composed
of the B23−B30 C-terminal segment of insulin that was
followed by the eight amino acids of the CII domain was
insoluble in solvents necessary for enzymatic semisynthesis.
Therefore, we focused here on the systematic enzymatic
semisynthesis of insulin analogues with the C-terminus of B
chain extended by one, two, three, and four residues from the
CII domain; they also contained Arg → Lys substitutions, with
lysine side chains temporarily Nε-protected by the Pac groups.
This approach was more successful, and the Pac Lys protection
was removed enzymatically with penicillin amidohydrolase after
the semisynthesis.43,46 However, some proteolytic side
reactions were also experienced here, probably because of a
prolonged Pac cleavage time that was required for the removal
of these multiple protective groups. Hence, the use of a cocktail
of protease inhibitors was needed because of the poor yield of
these reactions (in the range of 1.5−5%), as well.
Despite these synthetic diﬃculties, we made four (4−7) new
hybrid analogues of human insulin containing one to four CII
domain residues (with Arg → Lys substitutions); they were
subsequently characterized with all three types of receptors. We
expected that the addition of fragments of the CII domain to
insulin will enhance its binding to the “mitogenic” IR-A and
IGF-1R receptors, weakening simultaneously its interaction
with the “metabolic” IR-B isoform. Although only moderate,
and nonsigniﬁcant, increases in the binding aﬃnities of 4−7 for
IGF-1R were observed (Table 1) [paralleled by similar small
IGF-1R autophosphorylation eﬀects (Figure 4C)], the binding
aﬃnities and autophosphorylation ability of these analogues for
IR-A and IR-B were unexpected. Analogues 4−7 have
moderately decreased binding aﬃnities [from 43 to 88%
(Table 1)] for IR-A compared to HI, paralleled by their similar
ability to activate this receptor (Figure 4A). More surprising
were the equipotent, or slightly increased, IR-B binding
aﬃnities of analogues 4, 6, and 7, with only analogue 5 being
a signiﬁcantly weaker IR-B binder [33% (Table 1 and Figure
4B)]. Its lower binding aﬃnity for IR-B [33%, and to some
extent also for IR-A, as well (43%)] could be caused by a
negative eﬀect of the C-terminal LysB32. This eﬀect is similar
to the impact of the C-terminal arginine residues in insulin
glargine, which has two extra arginines at the C-terminus of the
B chain, and its IR-B binding aﬃnity is also lower than that of
HI.57−59 Some C domain-related reports suggest that the CI
domain (but not the CII domain) should be considered as an
important factor in hormone−IGF-1R binding, but with
negligible eﬀect on their IR binding.25 In contrast, the CII
domain was supposed to be critical for signaling through IR-
A.51 However, a slightly positive eﬀect of the CII domain on IR-
B binding was observed for the IGF-1 analogue with this whole
IGF-2 segment, as well.24
Interestingly, the IR-B autophosphorylation abilities of
analogues 4−6 do not fully follow their IR-B binding aﬃnities
as they are signiﬁcantly enhanced. Here, only analogue 7 has its
IR-B autophosphorylation ability proportional to its IR-B
binding aﬃnity (Figure 4B). The preferential activation of IR-B
by analogues 4−6 is interesting, as it was already indicated that
a relatively moderate IR isoform speciﬁcity of insulin analogues
may have a signiﬁcant impact on their biological eﬀects.12
Hence, IR-B-speciﬁc analogues could indeed present important
applications in assuring a more physiological proﬁle of clinical
insulins in vivo, with an enhanced hepatic mode of action.60
It should be stressed that the extra amino acids added to the
C-terminus of the B chain in analogues 4−7 might not
represent the true CII mimics, as their selection was signiﬁcantly
driven here by the semisynthetic yields. Our modiﬁcations
should be thus rather considered as new (but IGF-derived),
artiﬁcial structural motifs that add new properties to the insulin
molecule; this is diﬀerent from the “natural”, biological impact
of the CII domain. Nevertheless, they showed that the use of
even signiﬁcantly constrained/modiﬁed sequences within the
CII domain could result in protein probes that provide valuable
insight into the hormone’s functionality. Moreover, they could
open a new path into the design and creation of novel and
important analogues with enhanced IR-B speciﬁcity, needed for
clinical applications.
The preferential binding/autophosphorylation of IR-B by
analogues 4−7 evokes also questions about a direct interaction
of their B chain C-terminal “extra” residues (B31−B34) with α-
CT peptide of IR-B. The position of 12 amino acids of IR-B
exon 11 in the receptor structure is still unknown. However, it
can be assumed that the conformation of insulin B21−B27
residues (visible in the insulin:IR-A complex) on the L1 domain
may be similar upon binding to both IR isoforms. If this is
indeed the case, then a direct interaction between the C-
Biochemistry Article
DOI: 10.1021/acs.biochem.6b00140
Biochemistry 2016, 55, 2903−2913
2910
terminus of the insulin B chain and exon 11-encoded additional
IR-B residues cannot be excluded. Therefore, our results
concerning analogues 4−7, together with the recently
published evidence of the increased hormone’s IR-B sensitivity
obtained through modiﬁcation of the C-terminal part of the
insulin B chain,12,49,61 underline and indicate the importance of
this region for achieving IR-B-speciﬁc hormone analogues. This
opens new venues for a rational manipulation of the insulin
B26-onward part of the hormone, which was usually though to
be unimportant for its functionality. We show here that a
careful extension of the B chain beyond the B30 site can
introduce new and exciting properties into the insulin molecule.
In summary, our insulin-based hybrid hormonal probes with
elements of IGF-1 and IGF-2 presented here suggest that (i)
the DI domain plays a more negative role in binding to IR than
the DII domain does, (ii) DI domain P-L-K residues are a
determining factor for a diﬀerent IR-A and IR-B binding aﬃnity
of IGF-1 and IGF-2, and (iii) the addition of amino acids
“mimicking” the CII domain to the C-terminus of the insulin B
chain may result in an unexpected, speciﬁcally deepened,
autophosphorylation of “metabolic” IR-B. Our research
evidence underlines also the sophistication and complexity of
the insulin/IGF/IR/IGF-1R signaling system, in which
hormone:receptor binding and receptor activation strengths
are frequently not fully correlated and are, likely, modulated
further by the half-life of these complexes and their endocytotic
fate.
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